News | Cath Lab | May 12, 2021

Abbott’s New Artificial Intelligence OCT Coronary Imaging Platform Launches in Europe

New imaging platform merges optical coherence tomography (OCT) with the power of automation using artificial intelligence (AI)

Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting proc

Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.


May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.

Unlike traditional imaging methods such as conventional angiography, Abbott’s OCT technology uses near-infrared light to provide high-definition, precise imaging from within a blood vessel. OCT imaging also helps improve physicians’ assessment of blockages in those vessels and optimize decisions related to stent selection, placement and deployment. Through integration with Abbott’s new Dragonfly OpStar imaging catheter, Ultreon Software extends the reach of OCT by allowing physicians to capture information from even the most complex patient anatomy.

With the launch of Ultreon Software, Abbott is further leveraging OCT technology to help physicians make better treatment decisions for their patients. Recent data show that physicians altered their treatment strategy in 88% of coronary artery blockages based on new information provided by OCT when used with MLD MAX, a new workflow that helps guide stenting decisions and provide physicians with treatment strategies to optimize stent placement.[1]

"Ultreon’s customizable user interface and AI detection will make decision-making faster and reduce procedural variability, especially for the increasing number of physicians who are learning to utilize OCT imaging over other more traditional imaging technologies," said Jose Mª de la Torre Hernández, M.D., head of interventional cardiology at Hospital Universitario Marques de Valdecilla, Spain, and editor-in-chief of REC: Interventional Cardiology. "The automatic display of details with Ultreon reduces uncertainty during the preparation for stent placement and allows for increased accuracy to help us deliver better care to our patients."

Technology continues to be a vital part of improving patient care in the cardiovascular community. In an August 2020 study titled Beyond Intervention, physicians and administrators identified technology as a critical component to improving patient outcomes across the healthcare continuum. More than half of the interviewed physicians identified technology and data as having the greatest potential to support decision-making at diagnosis and when determining patient treatment.[2] Ultreon Software is an example of a technology designed to augment physician decision-making, particularly when combined with established tools providing comprehensive physiological assessment of coronary blood flow and severity of blockages, such as Resting Full-Cycle Ratio (RFR) and Fractional Flow Reserve (FFR)

"Increased adoption of OCT imaging, when combined with advanced technology like AI, allows cardiologists to have a more precise and measurable way of supporting patients undergoing coronary stent procedures," says Nick West, M.D., chief medical officer and divisional vice president of global medical affairs at Abbott’s vascular business. "Ultreon Software can potentially improve physician and patient experience by utilizing a systematic process, reducing variability and increasing accuracy of diagnosis and application of therapies."

The new Ultreon Software will be showcased for the first time at EuroPCR on May 18-21, 2021, during Abbott’s "Tools and Technique Sessions." Abbott also intends to seek approval in the U.S. and Japan.

For more information: www.abbott.com

 

Related AI in the Cath Lab Content:

VIDEO: Artificial Intelligence May Improve Cath Lab Interventions — Interview with Nick West, M.D.

Emerging Technology and Data Key to Closing Treatment Gaps to Improve Cardiovascular Care

VIDEO: Survey Shows Large Disconnect in Medical Technology Across Continuum of Care

OCT Imaging Changed Treatment Decisions in 88 Percent of Artery Blockages in New Study
 

References: 

1.  Jones, Daniel A. et al "Angiography Alone Versus Angiography Plus Optical Coherence Tomography to Guide Percutaneous Coronary Intervention." JACC: Cardiovascular Interventions 11.14 (2018): 1313-1321. Web. 23 Aug. 2018.

2. https://www.cardiovascular.abbott/us/en/campaigns/beyond-intervention.html

 
 


Related Content

News | Artificial Intelligence

July 25, 2024 — Nanox, an innovative medical imaging technology company, announced that the AI Cardiac Solution ...

Home July 25, 2024
Home
News | Artificial Intelligence

July 18, 2024 — HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) heart care solutions, introduced ...

Home July 18, 2024
Home
News | Artificial Intelligence

July 18, 2024 — AliveCor, a global leader in AI-powered cardiology, today announced that the American Medical ...

Home July 18, 2024
Home
News | Artificial Intelligence

July 17, 2024 — HeartFlow, a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced ...

Home July 17, 2024
Home
News | Artificial Intelligence

July 11, 2024 — Heart Test Laboratories, Inc. an artificial intelligence (AI)-powered medical technology company focused ...

Home July 11, 2024
Home
News | Artificial Intelligence

June 26, 2024 — Anumana, a leading AI-driven health technology company and portfolio company of nference, and InfoBionic ...

Home June 26, 2024
Home
News | Artificial Intelligence

June 25, 2024 — Nano-X Imaging (Nanox), an innovative medical imaging technology company, today announced that data from ...

Home June 25, 2024
Home
News | Artificial Intelligence

June 25, 2024 — AliveCor, the global leader in AI-powered cardiology, today announced the U.S. Food and Drug ...

Home June 25, 2024
Home
News | Artificial Intelligence

June 24, 2024 — HeartFocus, the revolutionary, AI-driven heart exam software by DESKi, a provider of automated, accurate ...

Home June 24, 2024
Home
News | Artificial Intelligence

June 21, 2024 — Cardiomatics, a pioneer in AI-powered ECG analysis solutions, and the Biotronik sales organization for ...

Home June 21, 2024
Home
Subscribe Now